ArticleInfection and drug resistance2018
Defining the potency of amikacin against
Article in Infection and drug resistance, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 26 citations in OpenAlex.
- Filtration-Based SERS With In Situ Gold Growth in Bacterial Microenvironment for Rapid Detection of Low-Level Bacteria.Small methods · 2026Article
- Article
- Demystify Carbapenem-resistant Acinetobacter baumannii Pneumonia Burden: 2-Year Cohort Study.Annals of African medicine · 2025Article
- Amikacin Coated 3D-Printed Metal Devices for Prevention of Postsurgical Infections (PSIs).Pharmaceutics · 2025Article
- Retrospective Analysis of Antimicrobial Resistance Trends in Pseudomonas aeruginosa and Acinetobacter baumannii.Cureus · 2024Article
- Antimicrobial resistance profiles ofJAC-antimicrobial resistance · 2024Article
- Extended Spectrum beta-Lactamase Bacteria and Multidrug Resistance in Jordan are Predicted Using a New Machine-Learning system.Infection and drug resistance · 2024Article
- Assessing Clinical Potential of Old Antibiotics against Severe Infections by Multi-Drug-Resistant Gram-Negative Bacteria Using In Silico Modelling.Pharmaceuticals (Basel, Switzerland) · 2022Review
- Sepsis Management in Southeast Asia: A Review and Clinical Experience.Journal of clinical medicine · 2022Review
- Coexistence of Virulence Factors and Efflux Pump Genes in Clinical Isolates ofInternational journal of microbiology · 2021Article
- Polymyxin B resistance rates in carbapenem-resistantExperimental and therapeutic medicine · 2020Article
- 3D microfluidic gradient generator for combination antimicrobial susceptibility testing.Microsystems & nanoengineering · 2020Article
- CusS-CusR Two-Component System Mediates Tigecycline Resistance in Carbapenem-ResistantFrontiers in microbiology · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesWe report the in vitro activity of amikacin and comparators against Gram-negative bacteria collected from blood and respiratory specimens in China during a 1-year period between December 2015 and December 2016. MATERIALS AND
methodsMinimum inhibitory concentrations (MICs) were determined by agar dilution methods using Clinical and Laboratory Standards Institute (CLSI) guidelines, and susceptibility was assessed using CLSI breakpoints, except for tigecycline against Enterobacteriaceae. A pharmacodynamic threshold MIC ≤ 256 mg/L was also applied for amikacin since its inhalation formulation has demonstrated activity up to these MICs.
resultsFor
conclusionAmikacin portrayed comparable or better susceptibility rates to most of the tested antibiotics against
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.